Source comparison
Tesamorelin vs Egrifta SV — Same Compound, Different Use Cases
A 2010 Phase 3 trial published in The Lancet found that tesamorelin reduced visceral adipose tissue by 15.2% in HIV patients with lipodystrophy. A result no other intervention had achieved. That trial led to FDA approval of Egrifta, the brand name for pharmace
This comparison does not assign a generated winner or score.
- A 2010 Phase 3 trial published in The Lancet found that tesamorelin reduced visceral adipose tissue by 15.2% in HIV patients with lipodystrophy. A result no other intervention had achieved. That trial led to FDA approval of Egrifta, the brand name for pharmaceutical-grade tesamorelin. But here's what most people miss: the molecule itself. Tesamorelin. Is a 44-amino-acid GHRH analogue that stimulates endogenous growth hormone (GH) release from the anterior pituitary. Egrifta is simply one commercial formulation of that molecule.
- Our team has worked with researchers exploring tesamorelin in non-HIV contexts. Body recomposition studies, metabolic health protocols, and IGF-1 modulation research. The confusion between 'tesamorelin' and 'Egrifta SV' isn't semantic. It reflects a misunderstanding of what FDA approval actually covers: a specific formulation for a specific indication, not a molecule's entire potential.
- What's the difference between tesamorelin and Egrifta SV?
- Tesamorelin is the active peptide compound. A synthetic analogue of human growth hormone-releasing hormone that binds to GHRH receptors in the pituitary gland, triggering endogenous GH release. Egrifta SV is the FDA-approved branded medication containing tesamorelin, indicated specifically for reducing excess abdominal fat in HIV patients with lipodystrophy. Research-grade tesamorelin is chemically identical but prepared for laboratory use under different regulatory pathways.
- The real distinction isn't pharmacological. It's regulatory and contextual. Egrifta SV is manufactured by Theratechnologies under FDA-approved Good Manufacturing Practices for a specific patient population. Research-grade tesamorelin is synthesized by facilities like Real Peptides for experimental protocols where the hypothesis being tested may extend beyond lipodystrophy. IGF-1 upregulation, lipolytic signaling, or lean mass preservation during caloric restriction. This piece covers the pharmacokinetics both versions share, the regulatory distinctions that separate them, and what those differences mean for protocol design.